Influenza A
74
1
6
51
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
15 trials with published results (20%)
Research Maturity
51 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.8%
5 terminated out of 74 trials
91.1%
+4.5% vs benchmark
14%
10 trials in Phase 3/4
29%
15 of 51 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 51 completed trials
Clinical Trials (74)
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test
CC-42344 Safety Study in Healthy Participants
Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations
Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China
Covid Flu A/B and RSV 4 in 1 Diagnostic Test
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A
Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings